Immune-related adverse events (irAEs) are a range of complications associated with the use
of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs widely used are Cytotoxic …

Immune-checkpoint inhibitors (ICIs) have transformed patient care in oncology but are
associated with a unique spectrum of organ-specific inflammatory toxicities known as …

PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

Immune checkpoint inhibitors (ICIs), as one of the innovative types of immunotherapies,
including programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), and …

Immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI)
therapy may vary substantially in their clinical presentation, including natural history …

Systemic therapy for advanced hepatocellular carcinoma has expanded at an
unprecedented pace over the past 5 years. After tyrosine kinase inhibitors dominated the …

Since their introduction into clinical practice a decade ago, immune checkpoint inhibitors
(ICIs) have had an overwhelming impact on cancer treatment. Use of these agents in …

T cell-based immunotherapy, which tackles T cell dysfunction and exhaustion, offers broad
promising for treating cancer. Various T cell-based immunotherapies, such as immune …

Objectives The incidence of real-world pneumonitis and durvalumab rechallenge during
chemoradiotherapy and durvalumab consolidation for non-small cell lung cancer is …

Abstract Purpose of the Review The reintroduction of immune checkpoint inhibitors (ICIs)
after disease progression (rechallenge) or immune-related adverse events (irAEs) …